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The successful development of a mucosal vaccine depends critically on the use of a safe
and effective immunostimulant and/or carrier system. This review describes the effective-
ness and mode of action of an immunostimulating particle, derived from bacteria, used in
mucosal subunit vaccines. The non-living particles, designated bacterium-like particles are
based on the food-grade bacterium Lactococcus lactis.The focus of the overview is on the
development of intranasal BLP-based vaccines to prevent diseases caused by influenza and
respiratory syncytial virus, and includes a selection of Phase I clinical data for the intranasal
FluGEM vaccine.
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INTRODUCTION
A key issue in the development of improved and new vaccines
is safety, since most vaccines are given to healthy individuals. In
order to improve safety profiles, the use of well-defined (recom-
binant) purified antigens for the generation of subunit vaccines
has become key in vaccine development programs. In addition,
there is an increasing interest to explore other modes of vaccine
administration besides the use of needles. Since purified solu-
ble antigens are usually poorly immunogenic, even more so when
delivered through mucosal (nasal, oral) routes, the addition of safe
immunostimulators/adjuvants to increase the efficacy of vaccines
is needed (1–3).
In order to minimize regulatory hurdles, we have developed a
non-living particle that can be used as an immunostimulant for
the improvement of existing vaccines and to enable mucosal appli-
cation, or can be used additionally as a vaccine carrier for subunit
antigens. The particles are based on non-recombinant Lactococcus
lactis bacteria. L. lactis is an innocuous Gram-positive bacterium
that is commonly used in the food industry; it has Generally Recog-
nized As Safe (GRAS) status of the Food and Drug Administration
(FDA). The safe background of L. lactis makes it highly suitable for
use in vaccines. The Gram-positive bacterial cell surface consists of
a single membrane on the inside and a thick cell-wall on the outside
(4, 5). The cell-wall is built up of multiple layers of peptidoglycan
(PGN) with various other components that may protrude both on
the inside and outside. A simple pretreatment in hot acid destroys
all cellular components, including intracellular components such
as DNA. Cell-wall components other than the rigid PGN matrix
are also degraded. The result is a non-living particle that retains
the same shape and size as the bacterium before treatment. Acid
treatment is followed by extensive washing with buffer to remove
acid and degradation products (6). The procedure results in non-
living spherical shaped bacterium-like particles (BLPs) that have a
diameter of approximately 1–2µm and consist predominantly of
a PGN outer surface (Figure 1).
As previously mentioned, BLPs are used in two different for-
mats. They are used as an immunostimulant by simply mixing
with vaccine antigens (admixed). This format is of particular inter-
est in the reformulation of existing vaccines to enable mucosal
application. The preferred format for use in recombinant sub-
unit vaccines is a formulation in which the antigens are bound
to the surface of BLPs. Binding of antigens to BLPs requires the
presence of a PGN binding tag (Protan) in the antigen. The PGN
binding domain of the L. lactis AcmA cell-wall hydrolase (7) has
been used for this purpose (8). Antigen-Protan fusions have been
produced in prokaryotic (L. lactis, E. coli) and eukaryotic hosts
(insect, CHO, and HEK cells). To date, over 40 different anti-
gens of bacterial, viral, or parasitic nature have been successfully
overexpressed as Protan fusions using these expression hosts (9).
The Protan fusions are secreted preferably by the expression cells,
allowing easy removal of the production cells. Conventional pro-
tein isolation techniques are then used to purify the Protan fusion
product. The purified fusion is subsequently mixed with BLPs
to allow binding. The BLPs with bound antigen-Protan fusion
are subsequently recovered, washed, and formulated in a suitable
buffer (Figure 1).
A more extensive overview of BLP and Protan characteristics
was recently published elsewhere (9).
IMMUNOGENICITY OF BLP-BASED VACCINES: IN VIVO
STUDIES
Although the focus of this paper is on the mucosal use of BLP-
based vaccines, Table 1 provides an overview of all mucosal and
parenteral BLP-based vaccines tested to date as a proof-of-concept
for immunogenicity and protection against pathogenic challenge.
The immunogenicity and protection capacity of both BLP-based
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FIGURE 1 | Overview of the production and use of BLPs. After treatment
in hot acid, degradation products and acid are removed by washing with
phosphate buffered saline (PBS). The BLPs are finally formulated in PBS.
Vaccines are made by BLPs admixed with antigens (this formulation is of
particular interest for the reformulation of existing vaccines) or antigens are
bound to the surface of the BLPs. For this latter format, it is a requirement
that the subunit antigens are produced as a fusion protein with the Protan
tag in a suitable production organism. Mixing of an antigen-Protan solution
with BLPs results in instant, strong, and stable non-covalent binding such
that BLPs are completely covered at the surface with the antigen.
admixed vaccines and vaccines in which the antigen was bound
to the BLPs has been tested extensively in various animal models.
The listed studies demonstrate robust antigen-specific systemic
immune responses after parenteral vaccination and both strong
local and systemic responses induced upon mucosal vaccination.
Furthermore, the induced immune responses have proven to be
protective against infections with specific pathogens, including
viruses, bacteria, and parasites.
MUCOSAL ADMINISTRATION OF BLP-BASED VACCINES AGAINST
RESPIRATORY VIRUSES
Most intensively studied and advanced BLP-based vaccines are for-
mulations against respiratory viruses including: seasonal influenza
vaccine (FluGEM) and Respiratory Syncytial Virus (RSV) vaccine
(SynGEM). In the following section we provide an overview of
the results of immunization and protection studies performed in
influenza- and RSV-animal models.
FluGEM in animal models
Influenza is an acute respiratory illness that mostly affects the
upper, and sometimes also the lower, respiratory tract and is caused
by the influenza virus. It represents an important, often underes-
timated public health problem and is associated with increased
general practice consultation rate, hospital admissions and excess
deaths (17). In addition, influenza has a high impact on health care
planning, and is also one of the major causes of increased absen-
teeism from work and school, and thus has significant economic
impact. Every year approximately 5–10% of the global population
is infected with influenza, while during a major epidemic the attack
rate might increase up to 50%. The World Health Organization
(WHO) has estimated that 3–5 million of annually infected people
develop a severe form of the disease and of those, 250,000–500,000
die (18).
Influenza virus is a negative-sense ssRNA virus and it belongs to
the family of Orthomyxoviridae (19). The virion is composed of an
external envelope derived from plasma membrane of the infected
cell that contains viral surface glycoproteins. Additionally, the viral
particle contains an internal core, composed of the viral genome
associated with specific proteins (20). The surface of the viral par-
ticle is covered by numerous protein spike-like projections. These
are molecules of hemagglutinin (HA) and neuraminidase (NA);
two major surface glycoproteins (20). Besides HA and NA, the
viral envelope also contains membrane protein 2 (M2) (20). In
addition to the envelope glycoproteins, the genome of influenza
virus also encodes the matrix protein (M1), viral polymerase pro-
teins, the nucleoprotein (NP), and a number of non-structural
proteins (20).
Vaccination is the most effective method of preventing
influenza virus infection and its potentially severe complica-
tions. Current influenza vaccination strategies are mostly based on
inactivated virus vaccines (subunit, split-virion, virosome, whole
inactivated virus), which are generally administered through intra-
muscular injection and induce antibodies against HA – one of the
two surface viral glycoproteins and the main antigenic component
of the virus (21). Parenterally administered vaccines usually induce
potent systemic responses, but no local, mucosal response at the
port of viral entry. This lack of induced mucosal response might
be a limitation of the protective capacity of such vaccines (22).
Our goal is the development of a mucosal, more specifically, an
intranasal influenza vaccine. In contrast to parenteral vaccination,
this route of vaccine administration would activate local mucosal
responses at the port of viral entry, e.g., secretory IgA (S-IgA),
in addition to systemic responses. Therefore, an intranasal vac-
cine may provide a powerful first line of defense against influenza.
This would lead to reduction of virus entry, but also to reduc-
tion in virus replication and shedding. Furthermore, intranasal
vaccination does not require trained health care personnel for the
administration of the vaccine and does not bear the risk of needle
stick injuries (23).
In order to achieve maximum immunogenicity when intro-
duced through the i.n. route, inactivated influenza vaccines require
the presence of immunostimulating compounds. Several adju-
vants have been extensively evaluated as potential candidates for
mucosal vaccination, such as nucleic acids and bacterial com-
ponents (e.g., toxins) (24, 25). Despite good immunogenicity
profiles, development of many of the aforementioned adjuvants
is hampered by safety and regulatory concerns (26). Therefore, a
safe adjuvant/immunostimulant, suitable for i.n. influenza vacci-
nation, with a good immunopotentiating capacity is still highly
desirable.
We have developed two types of intranasal influenza vaccines.
The first type, FluGEM-A (A stands for admixing), is based on
a mixture of BLPs with commercially available influenza vac-
cine antigen (subunit or split-virion vaccine). The second type,
FluGEM-B (B stands for bound), contains purified influenza HA
and/or M2 protein ectodomain (M2e) bound to BLPs, as described
in the Section “Introduction.” Both vaccines have been extensively
tested for safety and immunogenicity in animals, and FluGEM-A
has also been tested in a Phase I clinical trial (see Final Remarks of
this review).
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Table 1 | Overview of preclinical proof-of-concept studies performed using different BLP-based vaccine formulations.
Pathogen Antigen
formulation
Vaccination
route
Animal
model
Tested
parameter
Study outcome
IMMUNOGENICITY AND PROTECTION CAPACITY OF BLP-BASED VACCINES
Virus Influenza Subunit vaccine
mixed with BLPs
i.m. Mouse, rat,
rabbit, ferret
Correlate of protection Serum HI titers >40 with strong increase
compared to benchmarka (10)
Mouse i.n. Homologous
challenge
100% Protection, inhibition of viral replication
in the lungs (10)
i.n. Mouse, rat,
rabbit, ferret
Correlate of protection Serum HI titers >40 comparable to i.m.
benchmarka (11)
Split-virion
vaccine mixed
with BLPs
i.n. Mouse i.n. Homologous
challenge
100% Survival with strong reduction of lung
viral load (12)
Mouse i.n. heterologous
challenge
100% Protection with strong reduction of
lung viral load, superior compared to
benchmark (12)
Mouse Local mucosal
response
S-IgA titers in the lung, nose and vaginal
mucosa (11, 12)
Subunit vaccine
mixed with BLPs
i.g. Mouse Correlate of protection Serum HI titers >40 (13)
Mouse Local mucosal
response
S-IgA titers in intestinal and nasal lavages (13)
HA bound to
BLPs
i.m. Mouse Correlate of protection Serum HI titers >40, strong increase
compared to i.m. benchmarkb
i.n. Mouse Correlate of protection Serum HI titers >40 comparable to i.m.
benchmarkb
M2e bound to
BLPs
i.n. Mouse i.n. challenge 100% protection, strong induction of lung
viral loadc
NP bound to
BLPs
i.n. Mouse Cellular response Th1/Th2 balanced cellular response (IFNγ/IL4
ratio)c
RSV RSV F bound to
BLPs
i.n. Mouse,
cotton rat
Correlate of protection Virus neutralization titers measured in serum
(38)
Mouse,
cotton rat
i.n. challenge Strong reduction in lung virus titers (38)
Mouse Local mucosal
response
S-IgA titers in nasal washes (38)
Cotton rat Safety Absence of enhanced disease symptoms
(interstitial pneumonia, alveolitis) (38)
HBV HBsAg mixed
with BLPs
i.n. Mouse, rat Correlate of protection Serum titers >10 U/ml, comparable to i.m.
benchmarkc
Bacteria Streptococcus
pneumoniae
IgA1p, SlrA,
PpmA bound and
mixed to BLPs
i.n., i.m. Mouse Pulmonary challenge
(pneumonia model)
50–75% Protection associated with strong
reduction in bacteremia (14)
i.n. Challenge
(colonization model)
Strong reduction in nasopharyngeal
colonizationc
Yersinia pestis LcrV bound to
BLPs
i.n. Mouse i.v. Challenge 100% Protection (15)
i.g. Mouse i.v. Challenge Up to 85% protectiond
Shigella spp. IpaB, IpaD bound
to BLPs
i.n. Mouse Pulmonary challenge 100% Protection against S. flexneri in adults;
partial protection against S. flexneri in
newborns; 90% cross-protection against S.
sonneid
Parasites Plasmodium
berghei
CSP bound to
BLPs
i.m. Mouse Infected mosquito
challenge
100% Protection; sterile immunity (16)
RSV, respiratory syncytial virus; HBV, hepatitis B virus; i.m., intramuscular; i.n., intranasal; i.g., intragastric; i.v., intravenous; HI, hemagglutination inhibition; S-IgA,
secretory IgA; HA, hemagglutinin; M2e, M2 ectodomain; NP, nucleoprotein; F, fusion protein; HBsAg, HBV surface antigen; IgA1p, immunoglobulin A1 protease;
SlrA, streptococcal lipoprotein rotamase A; PpmA, proteinase maturation protein A; LcrV, low-calcium response virulence antigen; Ipa, invasion plasmid antigen; CSP,
circumsporozoite protein; aseasonal i.m. non-adjuvanted influenza subunit or split-virion vaccine; bmanuscripts in preparation; cmucosis, unpublished data; dPasetti,
unpublished data.
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Influenza antigen admixed with BLPs: FluGEM-A. To evaluate
the immunogenicity of FluGEM-A, mice were vaccinated i.n. with
FluGEM-A formulation, composed of seasonal subunit vaccine
mixed with BLPs. Control groups were i.m. (benchmark) or i.n.
vaccinated with a non-adjuvanted equivalent.
Immunogenicity of FluGEM-A vaccine. Intranasal vaccination
of mice with FluGEM-A induced serum hemagglutination inhi-
bition (HI) titers well above the determined protective titer of 40,
which was comparable with HI titers measured in the sera of ani-
mals vaccinated i.m. with seasonal subunit (benchmark) vaccine,
and significantly higher than titers induced by i.n. vaccination
with unadjuvanted subunit vaccine (11) (Figure 2A). Similarly,
influenza HA-specific IgG titers comparable to those induced
upon i.m. benchmark vaccination were measured in sera of mice
i.n. vaccinated with FluGEM-A (11). Importantly, subtyping of
influenza HA-specific IgG antibodies revealed that i.n. vaccina-
tion with FluGEM-A induced well-balanced responses, with an
IgG2a/IgG1 ratio of 0.9. Cytokine profiles assessed in spleens of
vaccinated animals were characterized by higher production of
Th1-polarized cytokines (IFN-γ and IL-2) and lower production
of IL-4, a Th2-polarized cytokine, when compared to cytokines
induced upon benchmark vaccination (11). Finally, i.n. immu-
nization with FluGEM-A, in contrast to benchmark vaccination,
induced strong local S-IgA responses, especially important as the
first line of defense at the port of virus entry (11, 12) (Figure 2B).
In addition to strong systemic and mucosal responses, i.n. vac-
cination with FluGEM-A induced immune responses that seem to
wane slower than the response induced upon i.m. vaccination with
a non-adjuvanted benchmark vaccine. As depicted in Figure 2C,
serum IgG titers induced by i.n. vaccination with FluGEM-
A remained stable throughout the follow-up period of almost
4 months after the final immunization and were still boostable.
This observation is suggestive of induction of influenza-specific
memory B-cells and the presence of long-lived antibody secret-
ing plasma cells. On the other hand, IgG titers induced by i.m.
benchmark vaccination after 4 months decreased to approximately
a quarter of the initial post-vaccination value.
Similar immunogenicity profiles and immunopotentiating
capacities of BLPs were demonstrated for FluGEM-A in other
animal models such as rats, rabbits, and ferrets (9).
Protection against homologous and heterologous challenge
induced by intranasal vaccination with FluGEM-A. The pro-
tection capacity of i.n. administered FluGEM-A vaccines was
assessed in homologous challenge studies using an influenza PR8
challenge model. To this end, mice were two or three times
i.n. vaccinated with FluGEM-A containing a PR8-derived split-
virion vaccine (12). Control mice were vaccinated i.m. or i.n.
with non-adjuvanted split-virion vaccine. Results of the study
clearly demonstrated that vaccination with two or three doses of
FluGEM-A vaccine confers solid protection against infection with
a homologous virus strain. The degree of protection (measured
as loss of body weight after challenge) was comparable to protec-
tion observed in the group vaccinated i.m. with the benchmark
split-virion vaccine. In contrast, i.n. vaccination with the non-
adjuvanted split-virion vaccine-induced only marginal protection,
observed in only 20% of vaccinated animals, which provides direct
evidence of the mucosal immunostimulating properties of BLPs.
Interestingly, although the observed degree of protection between
mice vaccinated i.n. with FluGEM-A and those vaccinated i.m.
with split-virion vaccine was similar, the measured lung virus titers
differed significantly between these two groups. More specifically,
in the lungs of mice vaccinated i.n. with FluGEM-A up to 100-
fold lower viral load was measured compared to lungs of mice
i.m. vaccinated with split-virion vaccine (Figure 3A). This is an
important observation, as it suggests that i.n. vaccination with
FluGEM-A might reduce the shedding of the virus by infected
individuals, and thus control the infection at the population level.
The protection level of an i.n. FluGEM-A vaccine against infec-
tion with a heterologous influenza virus was also tested (12). For
that purpose, mice vaccinated three times i.n. with FluGEM-A
containing influenza A/New Caledonia-derived split-virion vac-
cine were challenged with PR8 virus. The control group was i.m.
vaccinated with a A/New Caledonia-derived split-virion vaccine.
Complete protection was observed only in mice vaccinated with
FIGURE 2 | Magnitude and duration of FluGEM-A – induced immune
response. Groups of eight mice were vaccinated three times (day 0, 14, and
28) i.n. with FluGEM-A or with benchmark subunit vaccine administered
through i.n. or i.m. route. One vaccination dose contained 5µg HA and in
addition to antigen, FluGEM-A vaccine contained 0.3 mg BLPs. HI titers
(A) measured in the sera of mice i.n. vaccinated with FluGEM-A were
comparable to titers induced upon i.m. vaccination with benchmark subunit
vaccine, and higher in comparison to titers induced by i.n. administration with
subunit vaccine. S-IgA titers in lung washes (B) were measured in all the mice
vaccinated i.n. with FluGEM-A, while only three mice from i.n. subunit group
and none of the mice from i.m. subunit group had detectable lung S-IgA
titers. Serum IgG titers (C) induced by i.n. vaccination with FluGEM-A
remained stable throughout the 18-weeks post-immunization follow-up period
and were still boostable.
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FIGURE 3 | Virus titers measured in the lungs of mice exposed to
homologous and heterologous influenza challenge upon i.n. vaccination
with FluGEM-A. Groups of six mice were vaccinated three times (day 0, 14,
and 28) i.n. with FluGEM-A or i.m. with benchmark split-virion vaccine. Two
groups were vaccinated with vaccine derived from PR8 strain (A), and two
groups were vaccinated with vaccines derived from New Caledonia strain
(B). One vaccination dose contained 5µg HA and in addition to antigen,
FluGEM-A vaccine contained 0.3 mg BLPs. Three weeks after the final
immunization (day 49) mice were exposed to challenge with 100 TCID50 of
PR8 virus. Lung virus titers were determined 5 days post-challenge. Virus
titers measured after homologous challenge in the lungs of mice vaccinated
i.n. with PR8-derived FluGEM-A vaccine were up to 100-fold lower compared
to titers measured in lungs of mice vaccinated i.m. with PR8-derived
split-virion vaccine (A). Virus titers measured after heterologous challenge in
the lungs of mice vaccinated i.m. with New Caledonia-derived split-virion
vaccine were significantly higher than titers measured in the lungs of mice
vaccinated i.n. with New Caledonia-derived FluGEM-A vaccine (B). *p<0.05;
one-tailed Mann–Whitney U test (n=6).
i.n. FluGEM-A vaccine, while a partial protection was observed
in animals i.m. vaccinated with the split-virion vaccine. This
was also reflected in the lung viral load, which was significantly
higher in benchmark vaccinated mice (Figure 3B). One possi-
ble explanation for the better clearance of the virus upon both
homologous and heterologous influenza challenge in mice i.n.
vaccinated with FluGEM-A could be the presence of S-IgA anti-
bodies at the mucosal surfaces of vaccinated animals. It has been
shown by others that mucosal vaccination against influenza infec-
tion induces full protection, which was dependent on the presence
and abundance of mucosal S-IgA antibodies (27, 28).
Additional mucosal vaccination routes for delivery of FluGEM-
A were also explored. A good example of successful mucosal
vaccination with influenza subunit vaccine mixed with BLPs is
vaccination through the intragastric (i.g.) route (13). Intragastric
vaccination of mice with three doses of FluGEM-A containing a
seasonal influenza subunit vaccine, induced HI titers above the
established protective criterion (>40). High serum IgG and local
nasal and intestinal S-IgA titers were detectable 3 weeks after the
last vaccination. Similarly to i.n. vaccination, i.g. vaccination with
FluGEM-A induced a balanced IgG2a/IgG1 response.
These summarized data clearly demonstrate the immune-
stimulating properties of BLPs and the ability to convert conven-
tional influenza vaccines into effective mucosal vaccines. Impor-
tantly, the immune responses elicited by FluGEM-A provide solid
protection against both homologous and heterologous influenza
infections, and this protection seems to be superior to the protec-
tion observed after i.m. benchmark vaccination. Finally, mucosal
vaccination with FluGEM-A, but not i.m. benchmark vaccination,
has the capacity to induce robust local S-IgA responses at viral
port of entry, which may contribute to superior lung protection
after infection and reduced viral shedding.
Influenza antigen bound to BLPs: FluGEM-B. Another type
of BLP-based influenza vaccine is prepared by physical coupling
(non-covalent binding) of purified influenza antigen (e.g., HA,
M2e, NP) to the surface of BLPs, as described in the Section“Intro-
duction” of this review. The main aim of this approach is to also
use the BLP as a carrier that present the antigens in a biologically
active manner to the immune system. To this end, trimeric HA
influenza proteins with a Protan tag were produced in mammalian
cell expression systems. The HA-Protan fusion protein is able to
form trimers because of the presence of a synthetic multimer-
ization domain that replaces the native HA transmembrane and
cytoplasmic domains. The correctly folded trimeric HA-Protan
fusion protein is purified from the production medium and as
such bound to the surface of BLP (FluGEM-B). FluGEM-B with
trimeric HA is biologically active as demonstrated by its ability to
agglutinate red blood cells to a high extent (Figure 4A), in con-
trast to its monomeric counterpart bound to BLPs, which does not
display any hemagglutination properties (Figure 4B).
There are a few potential advantages of the FluGEM-B concept
over FluGEM-A. An important safety aspect is that the process
of FluGEM-B preparation allows for simple purification of the
recombinant HA protein from the host cells and does not require
material originating from (inactivated) viruses, which is required
for the preparation of FluGEM-A. Furthermore, the FluGEM-B
concept allows for inclusion of purified influenza (and non-
influenza) antigens other than HA. This would be particularly
beneficial for preparation of multivalent vaccines, e.g., influenza
pandemic vaccine based on combination of HA and more con-
served proteins (M2e, NP). Finally, it has been shown that phys-
ical coupling of soluble (recombinant) antigens to an adjuvant
enhances vaccine immunogenicity, by allowing the antigen to be
delivered to the same cell activated by the adjuvant (29, 30).
To probe the difference between FluGEM-A and FluGEM-B
regarding immunogenicity, we vaccinated mice i.n. with both
vaccine formulations, using influenza HA and M2e as antigens.
Control groups were i.n. vaccinated with the antigen only. Figure 5
depicts the results of the studies expressed as vaccine-induced
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FIGURE 4 | Biological activity of trimeric and monomeric HA-Protan
fusion protein bound to BLPs (FluGEM-B) expressed as hemaggluti
nation capacity (HAU). Trimeric HA bound to BLPs displays a high capacity
to agglutinate turkey red blood cells (A), while monomeric HA bound to BLPs
displays no hemagglutination property (B). This suggests that trimeric HA
bound to BLPs is properly folded and in biologically active conformation.
FIGURE 5 | Immune responses induced upon i.n. vaccination with
FluGEM-A and FluGEM-B. Groups of 10 mice were vaccinated i.n. with
HA- or M2e-based FluGEM-A or FluGEM-B. Vaccination dose in the case
of HA-based vaccines (A) was 1µg HA mixed with or bound to 0.3 mg
BLP. Animals received in total three doses (day 0, 10, and 20) and were
sacrificed 2 weeks after the final immunization (day 34). Vaccination dose
in the case of M2e-based vaccines (B) was 6µg M2e equivalent mixed
with or bound to 0.38 mg BLPs. Animals received in total three doses
(day 0, 21, and 42) and were sacrificed 3 weeks after the final
immunization (day 63). In both cases physical coupling of the antigen
(FluGEM-B) induced a significant increase in serum IgG titers. *p<0.05;
**0.01; one-tailed Mann–Whitney U test (n=10). (C) Mice (n=3) were
vaccinated three times (day 0, 21, and 42) i.n. with M2e-based
FluGEM-B vaccine containing 50µg M2e and 0.3 mg BLPs. Three weeks
after the final immunization mice were exposed to challenge with
4LD50 ×47 (H3N2) influenza virus. Animals were sacrificed 6 days
post-challenge and virus titers were evaluated as a protection parameter.
In lungs of all infected mice vaccinated i.n. with M2e-based FluGEM-B
decrease of viral load was observed, which indicates protection capacity
of the FluGEM-B vaccine.
influenza HA- (Figure 5A) or M2e-specific (Figure 5B) serum IgG
antibody titers. In both studies, only vaccination with FluGEM-
B formulations induced seroconversion in all the animals, while
vaccination with antigen (HA or M2e) alone induced low serum
IgG titers in only a few mice. Moreover, physical coupling of BLP
with the antigens contributed to further, approximately fourfold,
increase in IgG titers. Additionally, i.n. vaccination with M2e-
based (Figure 5C) and HA-based (to be published elsewhere)
FluGEM-B induced protection against virus challenge in vacci-
nated mice, as demonstrated by the decrease in lung viral load in
infected vaccinated animals.
Binding of antigen to BLPs presents the further refinement
of BLP-based vaccines, as it allows for easier preparation of
highly purified proteins with well-preserved biological activity.
This concept might also be beneficial for the preparation of
multivalent vaccines, as it allows for simple incorporation of dif-
ferent viral antigens in the same vaccine formulation. Finally, it
corroborates the assumption that subunit antigens require phys-
ical interaction with the adjuvant for optimal vaccine immuno-
genicity, as illustrated by the examples of HA- and M2e-based
vaccines.
Respiratory syncytial virus vaccine: BLP-RSV F (SynGEM)
Respiratory syncytial virus represents a very important target for
development of successful vaccine candidates, as it is the single
most important cause of viral bronchiolitis in infants and young
children and it is the world-wide leading cause of infant hospi-
talization (31). Furthermore, elderly and immune-compromised
individuals are also at high risk of developing severe RSV dis-
ease (32, 33). Currently, there is no vaccine available and the only
commercially available prophylactic treatment is based on the neu-
tralizing antibody Palivizumab (34, 35). Although there is a clear
unmet medical need, the development of a safe RSV vaccine has
been hampered for decades by the fiasco of the first RSV vaccine
developed, Formalin-inactivated RSV (FI-RSV) which induced
exacerbation of disease symptoms in a high percentage of vac-
cinated children and increased the rate of hospitalizations among
vaccinees, including some fatalities (36).
With respect to a candidate RSV vaccine, we are developing
an intranasal formulation, SynGEM, that is based on the RSV
fusion protein (RSV F) bound to BLPs. The choice of antigen
was based on the finding that RSV F protein is highly conserved
throughout different virus isolates (37) and the only available
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neutralizing antibody Palivizumab is directed against this anti-
gen. The F antigen in SynGEM was produced as a functional
trimeric prefusion F protein in a similar way as trimeric HA was
produced. The immunogenicity of SynGEM has been tested in a
mouse and cotton rat model. Interestingly, results of both mouse
and cotton rat immunization studies with SynGEM were well
in line with immunogenicity results obtained from immuniza-
tions of mice with FluGEM (11). More specifically, i.n. vaccination
with SynGEM induced robust systemic IgG and local S-IgA titers,
with a balanced IgG2a/IgG1 ratio. In contrast, i.m. vaccination
with FI-RSV induced no local S-IgA and a very low IgG2a/IgG1
ratio (<0.1), indicating an extremely Th2-polarized response (38).
Additionally, unlike i.m. vaccination with FI-RSV, mucosal vacci-
nation with SynGEM induced protective virus neutralizing titers,
which represent the accepted correlate of protection against RSV.
Finally, i.n. vaccination with SynGEM induced a similarly bal-
anced cytokine profile (IFN-γ/IL4 ratio), as observed upon i.n.
vaccination with FluGEM (11).
One of the most important criteria for a successful RSV vaccine
is safety in the context of absence of induction of enhanced dis-
ease symptoms. It has been suggested that increased production of
IL4 is responsible for exacerbation of disease symptoms, as man-
ifested by severe eosinophilia, lack of neutralizing antibodies and
lack of efficient cellular responses (e.g., cytotoxic T lymphocytes –
CTLs) (39, 40). Therefore, vaccination-induced IL4 levels are used
as a predictor of the potential immunopathology. An illustrative
example of severely Th2 skewed immune responses induced by
vaccination is immunization with alum-adjuvanted FI-RSV (41).
In contrast, i.n. vaccination with SynGEM induces very low lev-
els of IL4 and the cytokine profile is dominated by production
of IFN-γ, results that are clearly in line with those obtained with
i.n. FluGEM vaccination. Additionally, as expected based on the
cytokine profile, histopathological analyses in cotton rats indicated
that i.n. vaccination with SynGEM does not induce symptoms of
enhanced disease (38).
In summary, intranasal vaccination with SynGEM vaccine
that is based on trimeric RSV prefusion F protein bound to
BLPs, induces robust, well-balanced systemic and local humoral
responses. The induced responses were shown to be protective
against RSV infection, without inducing enhanced disease symp-
toms. Therefore, SynGEM represents a promising and safe RSV
vaccine candidate.
MODE OF ACTION OF BLPs
ACTIVATION OF INNATE IMMUNE SYSTEM
In Section “Immunogenicity of BLP-Based Vaccines: In vivo Stud-
ies” of this overview, examples of different vaccine formula-
tions (FluGEM-A, FluGEM-B, SynGEM) were shown, in which
mucosal BLP-based vaccines induce robust, long lasting adap-
tive immune responses. Successful activation of specific adaptive
immune responses relies on optimal activation of innate immune
responses, which controls and determines the development of spe-
cific adaptive response (42, 43). Dendritic cells (DCs) play a crucial
role in this process, by being the direct link between the innate
and adaptive responses (44). Activation of DCs typically results in
cytokine and chemokine production, which further on determine
the nature of cellular and humoral responses (45). Finally, only
mature and activated DCs have the capacity to (cross-) present the
target antigen to CD4+ and CD8+ T-cells (46). The capacity of
BLPs to stimulate the innate immunity was well demonstrated in
the study of Ramirez et al. (15). In vitro stimulation of murine
and human neonatal and adult DCs with BLPs induced matu-
ration of these cells, as illustrated by the increase in expression
of surface maturation markers (CD40, CD80, CD86, and MHC
class I for murine DCs; CD80, CD83, CD86, and HLA-DR for
human DCs). These results are summarized in Table 2. Upon
acquisition of a mature phenotype, DCs become capable of anti-
gen (cross-) presentation, which activates the cellular arm of the
adaptive immune response. In line with this dogma is the obser-
vation that DCs stimulated with BLPs display reduced capacity for
antigen uptake, which indicates that these cells became effective
antigen-presenters (15).
In addition to the induction of a mature phenotype, BLPs stim-
ulated these DCs to produce proinflammatory, Th1-promoting
and regulatory cytokines. Cytokines such as IL-12p70, TNF-α,
IL-10, IL-6, and IFN-γ were secreted by DCs as a response to
stimulation with BLPs (Table 2).
Importantly, DCs that have acquired a mature and activated
phenotype, as a consequence of stimulation by BLPs, are capable
of presenting a specific antigen to target CD4+ and CD8+ T-cells
(15). In the study of Ramirez et al. the Y. pestis LcrV model antigen,
was bound to BLPs (BLP-LcrV) and used for in vitro activation of
specific CD4+ and CD8+ T-cells. DCs stimulated with such a
BLP-associated antigen successfully (cross-) presented the anti-
gen to target cells, as illustrated by remarkable proliferation and
production of IFNγ. Additionally, intranasal immunization with
BLP-LcrV induced strong activation of antigen-specific antibody
secreting cells in the NALT, bone marrow and spleen. The latter
organs are considered to be reservoirs of vaccine-induced plasma
cells that support production and maintenance of circulating
antibodies.
Together, these findings imply that the immunostimulating
properties of BLPs rely mainly on the capacity to activate innate
immune responses, or more specifically DCs, which are the crucial
link between innate and specific adaptive responses. The capacity
to induce maturation and activation of antigen-presenting cells
(APCs) makes BLPs suitable for delivery of the associated anti-
gen for presentation in the context of MHC class I and/or MHC
class II.
INVOLVEMENT OF TLR2
As demonstrated, the basis for successful induction of robust adap-
tive immune responses by BLP-based vaccines is activation of
innate immune pathways. This is mainly mediated by non-specific
recognition of invading pathogens, pathogen-derived compo-
nents, or microbial-derived components in general. More specif-
ically, the innate immune response is activated by recognition of
common microbial associated molecular patterns (MAMPs) by
a family of innate immune receptors, such as family of Toll-like
receptors (TLRs) (47–49). As a result of recognition of MAMPs
by TLRs, an activated state of the innate immune cells is induced.
Activated innate immune cells are capable of shaping the adaptive
B- and T-cell-mediated responses, depending on the information
extracted from the activation signal (49).
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Table 2 | BLP-induced maturation and activation of mouse and human DCs.
BLP LPSm orTNFαh
Neonatal Adult Neonatal Adult
Mouse Human Mouse Human Mouse Human Mouse Human
BLPs INDUCE MATURATION AND ACTIVATION OF MOUSE AND HUMAN DCs
Markers (fold increase relative to non-stimulated control)
CD40m or CD83h 1.0 2.2 1.3 3.6 1.0 2.9 1.3 3.0
CD80 1.2 2.2 1.1 2.5 1.4 2.7 1.8 1.8
CD86 4.0 5.1 7.2 6.9 4.2 4.8 6.1 5.1
I-Adm or HLA-DRh 1.1 1.4 8.9 3.1 0.9 1.4 7.2 3.2
Cytokines (fold increase relative to non-stimulated control)
IL-12p70 1.7 2.3 1.7 1.6 2.1 1.5 1.6 2.0
TNFα 140.1 163.0 9.4 541.8 93.4 24.4 10.8 1119.7
IL-10 3.6 4.1 11.4 47.6 3.6 16.3 20.3 2.1
IL6 565.5 164.7 421.3 329.1 707.9 1108.3 428.6 1.6
IFNγm or IL-1βh 1.5 1.7 3.7 3.1 1.9 2.3 7.3 2.0
MCP1m or IL8h 1.4 58.9 1.7 13.4 2.9 125.5 1.7 2.6
Maturation and activation of neonatal and adult DCs were evaluated by measuring the upregulation of surface markers and production of specific cytokines. m, mouse;
h, human.
Toll-like receptors are expressed on the surface or in the endo-
somal compartment of innate immune cells, DCs in particular,
and their engagement typically induces cytokine and chemokine
production, activation of DCs and subsequent priming of adaptive
immune response (50–52). Examples of TLR ligands are: lipopep-
tides and peptidoglycan (TLR2),viral dsRNA (TLR3),LPS (TLR4),
flagelin (TLR5), viral ssRNA (TLR7), bacterial, or CpG DNA
(TLR9). Activation of TLRs initiates a signaling cascade directed
through the MyD88 and/or TRIF signaling adapters, which in turn
activates various transcription factors (49). Due to their innate
immune-stimulating properties, TLR ligands have been explored
as promising new-generation adjuvants.
An advantage of this new generation of vaccine adjuvants is
that their mode of action is well-understood and characterized.
The first TLR ligand explored as an adjuvant in a registered
vaccine formulation is the TLR4 ligand MPLA used in GSK’s
HBV vaccine Fendrix® and HPV vaccine Cervarix®. Moreover,
it has been shown that injection of healthy human subjects with
CpG 7909 induces systemic innate immune activation manifested
by expression of Th1-polarizing cytokines and IFN-inducible
chemokines (53).
Bacterium-like particles belong to this group of new-generation
immunostimulators, as its mode of action is well-defined and is
based on activation of innate receptor – TLR2, which is a mem-
brane surface receptor, specific for numerous bacterial, fungal, and
viral components. Some of the ligands for TLR2 include: Zymosan
(S. cerevisiae) (54), LPG (L. major) (55), LPP (56), and HSV (57).
Recognition of TLR2 ligand by the receptor initiates the internal-
ization of bound molecules by the endosome/phagosome system
and leads to cellular activation. Consequently, cells of the innate
immune system, e.g., DCs and macrophages, acquire functions of
non-specific immune defense. The most important cytokines par-
ticipating in this process of activation are TNF-α, IL-1α, IL-1β,
IL-6, IL-8, and IL-12. TLR2 is expressed on a broad spectrum of
different cells, such as monocytes, macrophages, DCs, microglia,
polymorphonuclear leukocytes, and B- and T- cells. It is also
expressed on the surface of airway epithelia, pulmonary alveoli,
and skin keratinocytes (58–61). Very often, TLR2 functions in
the form of a heterodimer, when it is associated with TLR1 or
TLR6 (62).
The evidence that BLPs activate TLR2 was obtained from
both in vitro (using TLR2-specific cell assays) and in vivo stud-
ies (immunization studies on TLR2−/− mice). For the in vitro
studies, HEK293T cells expressing human TLR2, 3, 4, 5, 7, 8, and
9 and mouse TLR7 and 9, were stimulated with BLPs. The results
showed that only the cell line expressing TLR2 responded to BLP
stimulation. This observation was corroborated by the fact that the
human DCs incubated with an anti-TLR2 antibodies showed a sig-
nificant decrease in IL-6 production upon incubation with BLPs.
These findings suggest that BLPs shape the immune response by
activating TLR2 on innate immune cells, e.g., DCs (15). The pre-
cise mechanism of the TLR2 activation by BLPs is not completely
understood and remains to be elucidated.
In addition to the indirect activation of adaptive responses
through the interaction with DCs, recent literature suggests that
TLR2 agonists also have a direct effect on the adaptive immune sys-
tem by interacting with TLR2 expressed on the surface of T-cells
(63). One of the consequences of this direct stimulation is induc-
tion of Th1-polarized effector responses (63). Furthermore, it has
been shown that TLR2 ligands can interact directly with TLR2 on
the surface of B-cells. Consequently, the MyD88 signaling cascade
within B-cells is initiated, which can trigger IFNγ production by
T-cells and T-cell dependent IgG2c/a antibody switch (64). There-
fore, BLPs possibly have an additional mode of action by inducing
Th1-polarized immune responses through direct interaction with
TLR2 present on T- and B-cells.
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In addition to the described in vitro studies, intranasal immu-
nizations of wild type (wt ) and TLR2 knockout mice (TLR2−/−)
were performed to determine the in vivo effects of the absence
of TLR2. This study confirmed that nasal vaccination of mice
with influenza split-virion vaccine mixed with BLPs (FluGEM-A)
induces local and systemic T- and B-cell responses in a TLR2-
dependent manner (Keijzer, personal communication). More
specifically, upon vaccination with FluGEM-A vaccine the num-
ber of IFNγ-producing cells in the local draining lymph nodes
and spleen was significantly reduced in TLR2−/−mice compared
to wt mice. Interestingly, absence of TLR2 in knockout mice only
moderately effected the IgG levels after vaccination. However, the
results of the study showed that class switch toward IgG2c anti-
body was closely dependent on the interaction of BLP with TLR2,
while the levels of IgG1 were very similar between the groups. In
line with the previously mentioned study (64), the lack of antibody
switch toward IgG2c is closely related to and can be explained by
the substantial decrease in IFNγ production in TLR2−/− mice,
as this cytokine plays a major role in potentiating IgG2a/c anti-
body isotype switch. Finally, lack of TLR2 signaling had a negative
impact on the development of local mucosal responses, as S-IgA
titers measured in nasal and vaginal lavages of TLR2−/− mice
vaccinated with FluGEM-A were largely absent (Table 3).
The summarized results provide evidence that the mucosal
immunostimulating activity of BLPs, in terms of robust activation
of both systemic and local immune responses, depends critically
on activation through (innate) TLR2 activation by BLPs.
SAFETY AND IMMUNOGENICITY OF BLP-BASED VACCINES
IN HUMANS: FluGEM-A PHASE I CLINICAL TRIAL
The safety, tolerability, reactogenicity (primary end-point), and
immunogenicity (secondary end-point) of intranasal FluGEM-A
vaccine composed of seasonal trivalent inactivated influenza vac-
cine (TIV, season 2009–2010) mixed with BLPs, was evaluated in
a randomized, double-blind, controlled phase I clinical trial in
male and female subjects aged between 18 and 49 years of age.
As a parallel control vaccine, i.n. administered non-adjuvanted
TIV antigen was used. Details of the study are prepared for
publication elsewhere. Primary safety end-points for FluGEM-
A were not distinguishable from those of plain unadjuvanted
TIV with respect to severity, duration, and number of adverse
events (AEs). No severe AEs were reported. Moreover, there was
no evidence of increased frequency of complaints after the sec-
ond administration, suggesting no cumulative effect of vaccination
with intranasal BLP-based vaccine. Based on the data summarized
above, we conclude that intranasal FluGEM-A vaccine tested in
human adults is safe and well tolerated as far as can be deter-
mined in a limited number of study subjects. As an exploratory
safety parameter the anti-lactococcal serum antibody response
before and after complete vaccination was measured in order to
determine the suitability of repeated use of BLP-based vaccines
in humans. In addition, we summarize below results of primary
and exploratory immunology analyses, obtained for the FluGEM-
A group vaccinated with 1.25 mg BLPs mixed with a standard
TIV antigen dose of 15µg HA per strain and the TIV antigen
only group with the same standard HA dose per strain as the
FluGEM-A group. The two study groups consisted of 15 subjects
each. The vaccine dose was administered in a volume of 250µl,
equally divided between two nostrils. Seasonal TIV was com-
posed of the following viral strains: A/California/7/2009 (H1N1),
A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. The subjects
received on day 0 and 21 a single intranasal dose of FluGEM-A
or TIV alone and were followed for 210 days post-vaccination.
The primary analysis of systemic immunogenicity was through
systemic HI titers against each of the included viral strains and
mucosal (nasal) influenza-specific S-IgA antibody levels. In addi-
tion, for exploratory purposes, antigen-specific IFNγ-producing
cells were enumerated among peripheral blood mononuclear
cells (PBMCs) collected on days 0, 7, 21, and 28 post-prime
vaccination.
FluGEM-A VACCINE IS SUITABLE FOR REPEATED VACCINATION:
RESPONSE AGAINST THE BLP CARRIER
Another important aspect of BLP-based vaccines is whether anti-
bodies against the L. lactis-derived immune-stimulating compo-
nent, are induced. These may possibly hamper (repeated) vac-
cination with BLP-based vaccines. For this purpose, the status
of L. lactis-specific antibodies prior- and post-vaccination was
determined.
In all the subjects, serum antibody titers against L. lactis pro-
teins were measured before the start of the vaccination (day 0)
and 3 weeks after the second vaccination (day 42). Pre-vaccination
levels of L. lactis-specific antibodies in all the subjects were high
(in the FluGEM-A group the mean pre-vaccination titer was
1.3× 104, with max= 4.2× 104 and min= 2.3× 103; in the TIV-
only group the mean pre-vaccination titer was 1.3× 104, with
max= 5.1× 104 and min= 0.8× 103). Figure 6 represents the
relative change in L. lactis-specific antibody titers 3 weeks after
the final vaccination showing that vaccination with FluGEM-A
did not increase the level of L. lactis-specific antibodies. In both
vaccination groups no changes in antibody titers were measured.
Thus, the results indicate that BLPs do not enhance the levels of
Table 3 | Immunostimulatory capacity of BLPs in vivo critically depends onTLR2 activation.
Mouse
type
IFNγ-producing cells
(per 106 cells)
IAV-specific B-cells
(per 106 cells)
Serum IgG
(µg/ml)
Serum IgG2c
(µg/ml)
Serum IgG1
(µg/ml)
S-IgA titer
LN Spleen LN Spleen Nasal lavage Vaginal lavage
BLP-INDUCED IMMUNE RESPONSE CRITICALLY DEPENDS ONTLR2 ACTIVATION
TLR2−/− 30 102 3 4 10.5 1.0 8.0 – 0.5
wt 98 2701 10 8 24.4 6.3 4.9 2.5 7.1
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L. lactis-specific antibodies, which suggests FluGEM-A and other
BLP-based vaccines are suitable for repeated administration.
IMMUNOGENICITY OF INTRANASALLY DELIVERED FluGEM-A VACCINE
The primary measured immunological parameters were serum HI
titers and mucosal (nasal) influenza-specific S-IgA against each of
the viral strains included in the vaccine. Additionally, in order to
characterize cellular immune responses upon vaccination, PBMCs
were tested for presence of IFNγ-secreting cells.
Hemagglutination inhibition titers
Serum HI titers represent the generally accepted surrogate marker
for evaluation of efficacy of influenza vaccines and vaccination
protocols. Table 4 summarizes results of HI geometric mean
titers (GMTs) and GMT ratios measured in all the study sub-
jects on day 0, 21, 42, and 210, regardless of their baseline HI
titers, against all the influenza strains included in the vaccine.
FIGURE 6 | Relative change in BLP-specific antibody titer after i.n.
vaccination with FluGEM-A. Blood samples were collected from all test
subjects and L. lactis-specific antibody titers were determined on study
days 0 (baseline titers) and 42. In both vaccination groups (i.m. TIV and i.n.
FluGEM-A) no increase in L. lactis-specific antibody titers due to vaccination
were measured.
A clear increase in HI titers against all strains present in the
vaccine was already observed after one i.n. administration with
FluGEM-A. No additional increase in titers was observed after
administration of the second vaccine dose. Although the titers
observed after FluGEM-A administration were higher for all
strains at each time-point, the HI levels obtained after admin-
istration with TIV-only were already surprisingly high. As shown
in Table 4, i.n. vaccination with FluGEM-A induced GMT ratios
>2.5, which were at least twice as high as the ratios recorded in
TIV-only group. Importantly, HI GMT titers ≥40 were achieved
in subjects i.n. vaccinated with FluGEM-A after administration
of only one vaccine dose. The titers against all three strains
remained stable throughout the whole follow-up period of almost
6 months, which is in line with previously presented results of
duration of immunity induced by vaccination of mice with
FluGEM-A.
Intranasal FluGEM-A vaccine fulfilled the EMA criteria for
a seasonal influenza vaccine, i.e., at least one criteria out of the
following was met: seroconversion in >40% of subjects, seropro-
tection (HI titers ≥40) in >70% of subjects, and mean geometric
increase in titer >2.5, for each influenza strain included in the
vaccine.
To describe the dynamics in HI titers more accurately, in
Figure 7 we depict the change in HI titers for all three influenza
strains after vaccination, measured in subjects with HI baseline
titers <10. For all three influenza strains, in particular B and
H3N2, vaccination with FluGEM-A induced higher-magnitude
responses, when compared to responses induced by i.n. vaccina-
tion with TIV-only vaccine. Additionally, GMTs induced upon i.n.
vaccination with control TIV vaccine did not (strain B) or barely
(strain H1N1) reach the protective threshold titer of 40.
Influenza-specific mucosal (nasal) IgA response
To evaluate the capacity of FluGEM-A to induce local mucosal
responses, influenza-specific S-IgA titers in nasal washes of vacci-
nated subjects were measured. Figure 8 summarizes the titers of
Table 4 | HI titers specific for all three influenza strains included in the vaccine.
Vaccination group TIV FluGEM-A
HI GEOMETRIC MEANTITERS AND RATIOTO BASELINETITERS
Study day 0 21 42 210 0 21 42 210
Influenza B strain
Number of subjects 13 13 13 13 10 10 10 10
HI GMT 10.5 29.9 32.4 50.6 8.5 48.1 47.8 63.9
HI GMT ratio 1.0 2.8 3.1 4.8 1.0 5.7 5.6 7.6
Influenza H1N1 strain
Number of subjects 11 11 11 11 11 11 11 11
HI GMT 10.4 49.5 53.8 40.8 23.2 118.0 109.9 131.7
HI GMT ratio 1.0 4.8 5.2 3.9 1.0 5.1 4.7 5.7
Influenza H3N2 strain
Number of subjects 15 15 15 15 12 12 12 12
HI GMT 13.2 197.2 243.7 179.5 23.1 261.9 287.0 244.3
HI GMT ratio 1.0 14.9 18.5 13.6 1.0 11.3 12.4 10.6
HI titers were measured on study days 0 (baseline) 21, 42, and 210.
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FIGURE 7 | Change in HI titers against (A) influenza B, (B) influenza
H1N1 (C) and influenza H3N2 upon vaccination. HI titers in sera of
study subjects were measured on study days 0 (baseline titers), 21, and
42. Only titers measured in subjects with baseline <40 are depicted. For
all three influenza strains, responses induced by i.n. vaccination with
FluGEM-A were faster and of higher-magnitude, when compared to
responses induced by i.n. vaccination with TIV (barely reach protective
titer of 40).
FIGURE 8 | Influenza-specific IgA titers measured in nasal lavages of
vaccinated subjects. Nasal lavages of study subjects were collected and
IgA titers assessed on study days 0 (baseline), 21, and 42. On both days 21
and 42 titers measured in nasal lavages of subjects vaccinated i.n. with
FluGEM-A were significantly higher than titers measured in lavages of
subjects vaccinated i.n. with TIV. Increase in nasal IgA titers in FluGEM-A
vaccination group relative to the baseline was approximately 100% by day
21. *p<0.05; one-tailed Mann–Whitney U test.
the nasal influenza-specific S-IgA antibodies. Only subjects with
S-IgA values available at all the time points are included in the
table.
An increase of approximately fourfold relative to the baseline
titers was recorded in the FluGEM-A group already on day 21. This
was associated with a high seroconversion rate of approximately
70%. In contrast, only a minor increase in influenza-specific S-
IgA levels was detected in nasal washes of some of the participants
in the control TIV group after vaccination. Thus, i.n. vaccination
with FluGEM-A induces, in addition to systemic response (HI
titers), a robust nasal S-IgA response.
Cellular (IFNγ) response
IFNγ is a cytokine whose immunostimulatory and immunomod-
ulatory functions are critical for both innate and adaptive immune
responses. To evaluate the IFNγ responses induced by vaccination
with FluGEM-A, PBMCs were collected from vaccinated subjects
on days 0, 7, 21, and 28 and the number of IFNγ-producing cells
were enumerated after restimulation with TIV. Figure 9 represents
the vaccination-induced increase in number of IFNγ-producing
cells, specific for H1N1 (Figure 9A) and H3N2 (Figure 9B)
influenza strains. Results are presented as a mean increase from
baseline (number of specific cells measured on day 0 per 106 cells)
with 95% confidence intervals depicted. Presented results show a
trend of increase in the number of specific IFNγ-producing cells
from day 0 to day 21 among PBMCs isolated from subjects vac-
cinated i.n. with FluGEM-A and the increase became significant
for both strains after the booster immunization. This trend and
significant increase at day 28 is not observed in PBMCs isolated
from subjects vaccinated i.n. with TIV and a plateau in the number
of IFNγ producing PBMCs in this vaccination group is reached
1 week after the primary vaccination.
We conclude that i.n. vaccination with FluGEM-A, in addi-
tion to activation of humoral immune response, and unlike i.n.
vaccination with TIV, stimulates cellular responses in human sub-
jects, as shown by a vaccine-induced increase in the number of
influenza-specific IFNγ-producing PBMCs.
FINAL REMARKS
Mucosal vaccines offer several advantages, as demonstrated by
the described BLP-based vaccines, in comparison to the current,
classical, injectable vaccines. Besides the ease of needle-free admin-
istration, mucosal vaccines are capable of inducing both systemic
and local responses at the surface of mucosae. In this way, these
vaccines already provide a first line of defense in the form of S-IgA
at the port of entry of most pathogens. Additionally, locally pro-
duced S-IgA antibodies have been suggested to be less sensitive to
antigenic variation (28) and may therefore provide broader protec-
tion. Our observations with FluGEM-A in heterologous challenge
studies seem to be in line with this hypothesis (12).
The limited immunogenicity data derived from the Phase I
clinical trial appears to confirm the promising preclinical data.
Subjects that received FluGEM-A via the i.n. route showed sys-
temic HI titers and local S-IgA responses. Induction of humoral
responses was associated with the production of the immunomod-
ulatory cytokine, IFNγ. Whether the local and systemic responses
induced in humans by mucosal vaccination with FluGEM-A
in particular and BLP-based vaccines in general will result in
www.frontiersin.org September 2013 | Volume 4 | Article 282 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Van Braeckel-Budimir et al. BLPs in mucosal subunit vaccine applications
FIGURE 9 | FluGEM-A induced increase in influenza H1N1- (A) and
H3N2-specific (B) IFNγ-producingT-cells. Blood samples were
collected from study participants on study days 0, 7, 21, and 28.
PBMCs were isolated and IFNγ-producing cells were enumerated by
ELISPOT assay. Results are presented as a mean increase from a
baseline (number of specific cells measured on day 0 per 106 cells)
with 95% confidence interval depicted. *p<0.05; two-tailed Student
t-test.
improved protection against influenza and other pathogen infec-
tions, respectively, now remains to be investigated in follow-up
trials.
Development of a new generation of mucosal adjuvants
and immunostimulatory platforms, of which BLPs are an
example, fuels the required evolution in vaccine design and
protection against pathogen infections. Well-understood modes
of action of such compounds allows for rational design
of safe and protective vaccines with the desired immune
responses.
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